PreveCeutical Medical Inc.

CA74141E1043

Pharmaceuticals

Market Closed - Canadian Securities Exchange Other stock markets 02:53:06 2024-04-26 pm EDT			5-day change	1st Jan Change
0.025 ^CAD	0.00%		+25.00%	0.00%

2023	PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program	CI
2023	PreveCeutical Medical Prepares For Proof of Concept Preclinical Study For Diabetes, Obesity Dual Gene Therapy Program	MT

PreveCeutical Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 29, 2023

PreveCeutical Medical Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was CAD 0.381189 million compared to CAD 0.601064 million a year ago. Basic loss per share from continuing operations was CAD 0.001.

Latest news about PreveCeutical Medical Inc.

PreveCeutical Medical Inc. Initiates Preparation of Preclinical Study for Its Diseases & Obtains Proof-Of-Concept Dual Gene Therapy Program	Dec. 04	CI
PreveCeutical Medical Prepares For Proof of Concept Preclinical Study For Diabetes, Obesity Dual Gene Therapy Program	Dec. 04	MT
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 20	CI
PreveCeutical & Endosane Announce Update on Intranasal CBD Application	23-09-18	MT
PreveCeutical Medical Inc. and Endosane Pharmaceuticals GmbH Announces Innovative Preclinical Approaches to Assess Brain Availability of CBD and Pharmacologically Relevant Doses Following Intranasal CBD Application	23-09-18	CI
PreveCeutical Medical Inc. Showcases Dynamic Evolution in AI Strategy	23-09-12	CI
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-24	CI
PrevCeutical Medical Provides Update	23-07-24	MT
PreveCeutical Medical Inc. Files Cyclic Peptides and Uses Thereof in EU and Australia	23-07-24	CI
PreveCeutical Medical Inc. Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof	23-06-28	CI
Preveceutical Medical Inc. Furthering the Progress of Its Patent Family Directed to Sol-Gel	23-05-30	CI
PreveCeutical Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-29	CI
PreveCeutical Medical Inc. Auditor Raises 'Going Concern' Doubt	23-04-30	CI
PreveCeutical Medical Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-30	CI
PreveCeutical Medical Inc. Appoints Shawn Sadler as Head of Artificial Intelligence	23-04-24	CI
PreveCeutical Medical Inc. Launches Clinical Artificial Intelligence Division	23-04-24	CI
Preveceutical Medical Inc. Appoints C. Evan Ballantyne to the Board of Directors	23-02-21	CI
PreveCeutical Medical Inc. Signs Sol-Gel License Agreement with Its Subsidiary PreveCeutical Pty Ltd	23-01-09	CI
PreveCeutical Medical Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-25	CI
Preveceutical Medical Inc. Announces Appointment of Kathleen Rotika to Board of Directors	22-10-20	CI
PreveCeutical Medical Inc. Announces Resignation of Sachin Nanavati as A Member of the Company's Board of Director, Effective September 16, 2022	22-09-15	CI
PreveCeutical Medical Inc. Appoints Mr. Sachin Nanavati to Board of Directors	22-09-06	CI
PreveCeutical Medical Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-24	CI
PreveCeutical Medical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-29	CI
PreveCeutical Medical Inc. Announces Management Changes	22-05-27	CI

Chart PreveCeutical Medical Inc.

Duration

Period

More charts

Company Profile

PreveCeutical Medical Inc. is a Canada-based health sciences company. The Companyâs principal business activity is the development of options for preventive and curative therapies utilizing organic and nature identical products. The Companyâs pipeline includes Cannabinoid Sol-Gel, Non-Addictive Analgesic, BSV Peptide Program and Dual Gene Therapy. Its Cannabinoid Sol-Gel is cannabinoid-based nose-to-brain delivery system that provides relief to a range of indications from pain, inflammation, seizures, and neurological disorders. Its BSV peptide program targets cancer progression. Its Non-Addictive Analgesic is an engineering non-addictive analgesic peptide for pain management. Its Dual Gene Therapy targets type 2 diabetes and obesity. The Companyâs subsidiary, PreveCeutical (Australia) Pty Ltd., manages its research programs.

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q4 2023 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
PREVECEUTICAL MEDICAL INC.	0.00%	9.78M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B